Clinical Trial: SGLT2 INHIBITION for CARDIOVASCULAR ENDPOINT REDUCTION in HYPERTENSION

U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT06804161) titled 'SGLT2 INHIBITION for CARDIOVASCULAR ENDPOINT REDUCTION in HYPERTENSION' on Jan. 27.

Brief Summary: Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically use...